{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T05:08:29Z","timestamp":1783573709403,"version":"3.55.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2006,7,1]],"date-time":"2006-07-01T00:00:00Z","timestamp":1151712000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,10]],"date-time":"2019-12-10T00:00:00Z","timestamp":1575936000000},"content-version":"vor","delay-in-days":4910,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2006,7]]},"DOI":"10.1093\/annonc\/mdl071","type":"journal-article","created":{"date-parts":[[2006,4,7]],"date-time":"2006-04-07T00:13:06Z","timestamp":1144368786000},"page":"1158-1165","source":"Crossref","is-referenced-by-count":17,"title":["A phase I dose-finding clinical pharmacokinetic study of an oral formulation of irinotecan (CPT-11) administered for 5 days every 3 weeks in patients with advanced solid tumours"],"prefix":"10.1016","volume":"17","author":[{"given":"H.","family":"Dumez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Awada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Piccart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Assadourian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Semiond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Guetens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"de Boeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.A.A.","family":"Maes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.A.","family":"de Bruijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"van Oosterom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdl071_bb0010","first-page":"4385","article-title":"DNA topoisomerase I-mediated DNA cleavage and cytotoxicity of camptothecin analogues","volume":"49","author":"Hsiang","year":"1989","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdl071_bb0015","first-page":"1465","article-title":"Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relation to antitumour activity","volume":"49","author":"Jaxel","year":"1989","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdl071_bb0020","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1200\/JCO.1993.11.5.909","article-title":"Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group","volume":"11","author":"Shimada","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdl071_bb0025","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1200\/JCO.1996.14.4.1128","article-title":"Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer","volume":"14","author":"Rothenberg","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdl071_bb0030","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1200\/JCO.1997.15.8.2910","article-title":"Phase II trial of irinotecan in patients with metastatic colorectal carcinoma","volume":"15","author":"Pitot","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdl071_bb0035","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1200\/JCO.1997.15.1.251","article-title":"Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy","volume":"15","author":"Rougier","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdl071_bb0040","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/S0140-6736(98)03085-2","article-title":"Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer","volume":"352","author":"Rougier","year":"1998","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdl071_bb0045","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S0140-6736(98)02309-5","article-title":"Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer","volume":"352","author":"Cunningham","year":"1998","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdl071_bb0050","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1002\/(SICI)1097-0142(19990215)85:4<786::AID-CNCR5>3.0.CO;2-9","article-title":"A multicentre, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma","volume":"85","author":"Rothenberg","year":"1999","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdl071_bb0055","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/S0959-8049(98)00353-0","article-title":"Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU","volume":"35","author":"Van Cutsem","year":"1999","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdl071_bb0060","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S0140-6736(00)02034-1","article-title":"Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial","volume":"355","author":"Douillard","year":"2000","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdl071_bb0065","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJM200009283431302","article-title":"Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer","volume":"343","author":"Saltz","year":"2000","journal-title":"Irinotecan Study Group. N Engl J Med"},{"key":"10.1093\/annonc\/mdl071_bb0070","doi-asserted-by":"crossref","first-page":"4195","DOI":"10.1200\/JCO.2001.19.22.4195","article-title":"Randomized multicentre phase II study comparing a combination of fluorouracil and folinic acid and alternating irinotecan and oxaliplatin with oxaliplatin and irinotecan in fluorouracil-pretreated metastatic colorectal cancer patients","volume":"19","author":"Becouarn","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdl071_bb0075","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1200\/JCO.2002.20.1.165","article-title":"Randomized multicentre phase II trial of oxaliplatin plus irinotecan versus raltitrexed as first-line treatment in advanced colorectal cancer","volume":"20","author":"Scheithauer","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdl071_bb0080","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1200\/JCO.2002.08.015","article-title":"Triplet combination with irinotecan plus oxaliplatin plus continuous-infusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: a multicentre phase II trial","volume":"20","author":"Souglakos","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdl071_bb0085","article-title":"Phase I\/II study of escalating doses of irinotecan (CPT-11) in combination with UFT\/folinic acis (FA) in patients with advanced colorectal cancer (ACRC)","volume":"20","author":"Castellano","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdl071_bb0090","article-title":"Ongoing phase II trial with two schedules of irinotecan (CPT-11) in combination with capecitabine as first-line chemotherapy in patients with advanced colorectal cancer (ACRC)","volume":"20","author":"Cassata","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdl071_bb0095","article-title":"Extended phase I study of capecitabine in combination with a weekly schedule of irinotecan as first-line chemotherapy in metastatic colorectal cancer","volume":"20","author":"Sleucher","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdl071_bb0100","first-page":"11","article-title":"Preclinical evaluation of CPT-11 and its active metabolite SN-38","volume":"23","author":"Lavelle","year":"1996","journal-title":"Semin Oncol"},{"key":"10.1093\/annonc\/mdl071_bb0105","doi-asserted-by":"crossref","first-page":"606","DOI":"10.2165\/00003495-199652040-00013","article-title":"A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer","volume":"52","author":"Wiseman","year":"1996","journal-title":"Drugs"},{"key":"10.1093\/annonc\/mdl071_bb0110","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1200\/JCO.1995.13.1.210","article-title":"Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients","volume":"13","author":"Abigerges","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdl071_bb0115","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1200\/JCO.1997.15.3.1080","article-title":"High dose-intensity of irinotecan administered every 3 weeks in advanced cancer patients: a feasibility study","volume":"15","author":"Merrouche","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdl071_bb0120","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1200\/JCO.1999.17.6.1897","article-title":"Phase I and pharmacokinetic study of irinotecan administered as a low-dose, continuous intravenous infusion over 14 days in patients with malignant solid tumours","volume":"17","author":"Herben","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdl071_bb0125","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1200\/JCO.2000.18.3.659","article-title":"Phase I and pharmacologic study of irinotecan administered as a 96-hour infusion weekly to adult cancer patients","volume":"18","author":"Takimoto","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdl071_bb0130","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/BF00686188","article-title":"Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumours","volume":"36","author":"Houghton","year":"1995","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1093\/annonc\/mdl071_bb0135","first-page":"423","article-title":"Efficacy of systemic administration of irinotecan against neuroblastoma xenografts","volume":"3","author":"Thompson","year":"1997","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdl071_bb0140","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1038\/bjc.1997.491","article-title":"Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development","volume":"76","author":"Gerrits","year":"1997","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdl071_bb0145","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0959-8049(01)00371-9","article-title":"Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer","volume":"38","author":"Borner","year":"2002","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdl071_bb0150","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/00001813-199704000-00002","article-title":"Efficacy of oral irinotecan against neuroblastoma xenografts","volume":"8","author":"Thompson","year":"1997","journal-title":"Anticancer Drugs"},{"key":"10.1093\/annonc\/mdl071_bb0155","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1200\/JCO.1999.17.2.685","article-title":"Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumours","volume":"17","author":"Drengler","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdl071_bb0160","article-title":"A phase I and pharmacokinetic (PK) trial of oral formulation of irinotecan administered daily for 5 days every 3 weeks in patients (Pts) with solid tumours","volume":"20","author":"Dumez","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdl071_bb0165","article-title":"A phase I and pharmacokinetic (PK) trial of oral formulation of irinotecan administered daily for 14 days every 3 weeks in patients (pts) with solid tumours","volume":"20","author":"Schoemaker","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdl071_bb0170","article-title":"A phase I and pharmacokinetic study of a powder-filled capsule (PFC) formulation of oral irinotecan (CPT-11) given daily for 5 days every 3 weeks in patients with advanced solid tumours","volume":"20","author":"Pitot","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdl071_bb0175","article-title":"A phase I and pharmacokinetic study of powder-filled capsule formulation of oral irinotecan (CPT-11) given daily for 14 days every 3 weeks in patients with advanced solid tumours","volume":"20","author":"Sharma","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdl071_bb0180","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0378-4347(98)00270-9","article-title":"Simultaneous determination of the lactone and carboxylate forms of the camptothecin derivative CPT-11 and its metabolite SN-38 in plasma by high-performance liquid chromatography","volume":"718","author":"Chollet","year":"1998","journal-title":"J Chromatogr B"},{"key":"10.1093\/annonc\/mdl071_bb0185","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S1570-0232(03)00574-9","article-title":"Determination of irinotecan (CPT-11) and SN-38 in human whole blood and red blood cells by liquid chromatography with fluorescence detection","volume":"795","author":"de Jong","year":"2003","journal-title":"J Chromatogr B"},{"key":"10.1093\/annonc\/mdl071_bb0190","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1200\/JCO.2001.19.5.1501","article-title":"Irinotecan in the treatment of colorectal cancer: clinical overview","volume":"19","author":"Vanhoefer","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdl071_bb0195","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/oxfordjournals.annonc.a059109","article-title":"Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials","volume":"6","author":"Chabot","year":"1995","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdl071_bb0200","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1200\/JCO.1997.15.4.1502","article-title":"Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients","volume":"15","author":"Gupta","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdl071_bb0205","first-page":"50","article-title":"UFT plus leucovorin vs 5-FU plus leucovorin for metastatic colorectal cancer","volume":"11","author":"Carmichael","year":"1997","journal-title":"Oncology (Huntingt)"},{"key":"10.1093\/annonc\/mdl071_bb0210","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2165\/00003495-199958003-00011","article-title":"Tegafur\/uracil + calcium folinate in colorectal cancer: double modulation of fluorouracil","volume":"58","author":"Hoff","year":"1999","journal-title":"Drugs"},{"key":"10.1093\/annonc\/mdl071_bb0215","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1200\/JCO.2001.19.21.4097","article-title":"Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study","volume":"19","author":"Van Cutsem","year":"2001","journal-title":"J Clin Oncol"},{"issue":"Suppl 6","key":"10.1093\/annonc\/mdl071_bb0220","first-page":"296","article-title":"CPT-11 in combination with capecitabine as first-line therapy for metastatic colorectal cancer. Eu","volume":"37","author":"Kerr","year":"2001","journal-title":"J Cancer"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419453787?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419453787?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/17\/7\/1158\/563191\/mdl071.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T10:06:56Z","timestamp":1624442816000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419453787"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,7]]},"references-count":43,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2006,7]]}},"alternative-id":["S0923753419453787"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdl071","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2006,7]]}}}